Phathom Pharmaceuticals says FDA approved Voquezna Triple Pak and Dual Pak for treatment of Heliobacter pylori infection in adults.
- Shares rose 8.7% in post-market trading
- Phathom in-licensed the U.S., European, and Canadian rights to vonoprazan, an ingredient in Voquezna, from Takeda
- Phathom Pharmaceuticals Inc. rose 12.4% in postmarket trading to $16.45 as of 5:46 p.m. New York time
- The average 12-month price target of $52.67 is 220.2% above the current price
- 6 buys, 1 holds, 0 sells
To view the source of this information, click
To contact the reporter on this story: